Sisram Medical Ltd (HKG:1696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.380
+0.020 (0.85%)
Jun 18, 2026, 4:08 PM HKT
Market Cap1.11B -42.4%
Revenue (ttm)2.84B +4.7%
Net Income148.01M -24.3%
EPS0.32 -24.3%
Shares Out 468.34M
PE Ratio7.53
Forward PE4.13
Dividend0.10 (3.99%)
Ex-Dividend DateAug 26, 2025
Volume553,600
Open2.380
Previous Close2.360
Day's Range2.260 - 2.380
52-Week Range2.260 - 8.070
Beta0.65
AnalystsStrong Buy
Price Target4.40 (+84.87%)
Earnings DateMar 23, 2026

About Sisram Medical

Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment... [Read more]

Sector Healthcare
Founded 1999
Employees 1,047
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1696
Full Company Profile

Financial Performance

In 2025, Sisram Medical's revenue was $365.35 million, an increase of 4.65% compared to the previous year's $349.11 million. Earnings were $19.02 million, a decrease of -24.32%.

Financial numbers in USD Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 1696 stock is "Strong Buy." The 12-month stock price target is $4.40, which is an increase of 84.87% from the latest price.

Price Target
$4.40
(84.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sisram Medical Investor Day Key Takeaways

Advancing Global Medical Aesthetics Strategy and Unl ock ing Wellness Platform Value HONG KONG, May 27, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness ...

25 days ago - PRNewsWire

Sisram Medical Earnings Call Transcript: H2 2025

Revenue grew 4.7% to $365M in 2025, led by APAC and injectables, while North America declined. Gross margin fell to 58.9% due to tariffs and mix, but adjusted net profit rose 7.9%. DAXXIFY launched in China, and AI-enabled solutions expanded globally.

3 months ago - Transcripts

Sisram Medical Earnings release: H2 2025

Sisram Medical released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.

3 months ago - Filings

Sisram Medical Slides: H2 2025

Sisram Medical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.

3 months ago - Filings

Sisram Medical Annual report: H2 2025

Sisram Medical has published its H2 2025 annual report on March 24, 2026.

3 months ago - Filings

Sisram Medical Reports Solid Growth in 2025

Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with exp...

3 months ago - PRNewsWire

Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026

Earnings Conference Call to be Held on March 24, 2026 HONG KONG, March 12, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively refe...

3 months ago - PRNewsWire

Alma, a Sisram Medical Company, Advances the Future of Intelligent Aesthetics at IMCAS World Congress 2026

New clinical evidence highlights a smarter, technology-driven approach to scar management, rejuvenation, and tattoo removal HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or...

4 months ago - PRNewsWire

Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China

HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offeri...

5 months ago - PRNewsWire

Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; tog...

5 months ago - PRNewsWire

Sisram Medical Launches Universkin by Alma in Hong Kong, Pioneering a New Era of AI-assisted Personalized Skincare

HONG KONG , Nov. 21, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...

7 months ago - PRNewsWire

Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses

HONG KONG , Oct. 28, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...

8 months ago - PRNewsWire